Sonnet BioTherapeutics Holdings, Inc. (SONN) |
|
1.16 0.05 (4.5%)
|
01-27 16:00 |
|
Open: |
1.1 |
Pre. Close: |
1.11 |
|
High:
|
1.17 |
Low:
|
1.1 |
|
Volume:
|
114,380 |
Market Cap:
|
9(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:06 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.63 One year: 1.96 |
| Support: |
Support1: 0.93 Support2: 0.78 |
| Resistance: |
Resistance1: 1.39 Resistance2: 1.67 |
| Pivot: |
1.25  |
| Moving Average: |
MA(5): 1.13 MA(20): 1.23
MA(100): 1.42 MA(250): 3.02 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 15.6 %D(3): 15.7 |
| RSI: |
RSI(14): 47.7 |
| 52-week: |
High: 9.38 Low: 0.23 |
| Average Vol(K): |
3-Month: 3,072 (K) 10-Days: 226 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SONN ] has closed above bottom band by 29.1%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.17 - 1.18 |
1.18 - 1.18 |
|
Low:
|
1.08 - 1.09 |
1.09 - 1.1 |
|
Close:
|
1.15 - 1.16 |
1.16 - 1.17 |
|
Company Description |
|
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey. |
Headline News |
Sat, 28 Jan 2023
All you need to know about Zack Tinker's role on Fire Country ... - NewsBreak Original
Sat, 28 Jan 2023
Greedy, selfish, rich jerks - Freethought Blogs –
Thu, 26 Jan 2023
Goodpasture athletic trainer Chris Snoddy remembered as 'one of a ... - Main Street Preps
Wed, 25 Jan 2023
Seniors seize their chance to write and direct, one scheme at a time - The Sagamore
Tue, 24 Jan 2023
Byzantine tax laws help rich people — like the Getty family — shield ... - KCRW
Thu, 19 Jan 2023
$SONN Sonnet Biotherapeutics Holdings Inc Files For Common ... - CML News
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
6.2e+006 (%) |
|
% Held by Institutions
|
2.1 (%) |
|
Shares Short
|
322 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.966e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-8 |
|
Return on Assets (ttm)
|
478.3 |
|
Return on Equity (ttm)
|
-106.5 |
|
Qtrly Rev. Growth
|
349940 |
|
Gross Profit (p.s.)
|
-147.46 |
|
Sales Per Share
|
-510.89 |
|
EBITDA (p.s.)
|
-3.57458e+007 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-28 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
-1.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
14270 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-04-01 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
